Coherence reprograms cancer from within. With a new name, a new story and two decks from seed to $45M.

When Coherence first came to DreamLab in 2023, they were Opto Bio, with a proof of concept for SOMA-1, a closed-loop implant that treats glioblastoma from within. We designed their seed deck. After the round closed, they came back. The science was formidable, but the story was caught between dense neuroscience and speculative biohacking. With Series A ahead, it had to become undeniable.










We renamed them Coherence, a promise to the patients they will serve, and rebuilt everything around it: the narrative, the brand identity and the website. An image with SOMA-1 on a patient didn’t exist yet, so we created its first visualisation and built the story around it. The device had to feel believable and inevitable without losing its edge. Then we carried it into their Series A deck, and Coherence went on to raise $45M.









